Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced −Highlights Phase 2 data for ATH434 in Multiple System ...

After years of misdiagnosis, Rod Fussinger was finally diagnosed with Anti-IgLON5 Associated Autoimmune Encephalitis, and ...

After witnessing my father’s tortuous battle with the illness I wanted to understand my own risk, so I visited a brain expert ...

Molecular imaging is redefining in vivo characterization of multiple sclerosis, a demyelinating disease with complex and heterogeneous clinical profiles. Recent advances in PET tracers enable more ...

FDA approvals, trial progress and early commercial momentum put several ASX healthcare companies in a strong position heading ...

For decades, multiple sclerosis (MS) has been defined primarily by its symptoms, rather than its underlying biology. Now, a ...

What are the often invisible cognitive consequences of multiple sclerosis? Maureen van Dam mapped these out during her ...

After up to three years on GA Depot, most people with PPMS have not experienced any disability progression, according to new ...

A collaborative team of researchers and students from Wayne State University's Eugene Applebaum College of Pharmacy and ...

Modern disease is complex and individual. Biopharma offers a biological approach to more precise, effective treatment ...

A woman in her 60s with a history of atrial fibrillation, hypertension and dyslipidaemia was admitted to the Intensive Care ...

The HELIOS-B trial previously showed that vutrisiran (Amvuttra; Alnylam Pharmaceuticals), a gene-silencing therapy that ...